Microwave Ablation Feasibility for pancreatic and liver cancers guided by endoscopic ultrasound

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study uses an endoscopic ultrasound-guided microwave ablation (MWA) device to treat tumors that are accessible through the gastric wall. The main goals are to assess how well energy is delivered during the procedure and to evaluate short-term safety and potential antitumor effects. Eligible participants include adults with histologically confirmed locally advanced or metastatic cancer with at least one tumor ≥1 cm suitable for MWA. The trial will monitor procedural feasibility, safety, and preliminary signs of tumor response across multiple U.S. sites. Lead sponsor is Banner Health, with collaboration from Creo Medical and related entities.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female ≥18 years of age
* Willing and able to provide written informed consent
* Histologically confirmed locally advanced, unresectable or metastatic cancer (Stage III or IV)
* At least 1 tumor that is indicated for MWA, and the location of target tumor must be accessible via EUS through the gastric wall (eg, pancreas, liver, etc).
* The tumor(s) must be ≥1 cm in diameter

Exclusion Criteria:

* Participant is a candidate for upfront resection of pancreatic cancer
* Participation in another clinical trial that involves local ablation or any other local therapy that could affect the target organ or lesions treated in this study
* Any condition that, in the opinion of the investigator, may increase the risk to the participant's safety or well-being

Where it's running

• Banner MD Anderson Cancer Center and Gateway Hospital
  Gilbert, Arizona, United States Recruiting
• Cedars Sinai
  Los Angeles, California, United States Not yet recruiting
• Rush University Medical Center
  Chicago, Illinois, United States Not yet recruiting
• University of Tennessee Medical
  Knoxville, Tennessee, United States Not yet recruiting
• Memorial Hermann-Texas Medical Center
  Houston, Texas, United States Not yet recruiting
• West Virginia University Medicine
  Morgantown, West Virginia, United States Not yet recruiting

Study contacts

• Principal investigator: Neil Sharma, MD — Banner Health (Banner MD Anderson Cancer Center at Gateway Medical Center)
• Study coordinator: Neil Sharma, MD
• Email: neil.sharma@bannerhealth.com
• Phone: (480) 356 - 6444

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using virtual reality to help manage pain in GI cancer patients

  This study is testing if virtual reality can help people with GI cancer manage their severe abdominal pain better than standard treatments.

  Recruiting Cedars-Sinai Medical Center · Los Angeles, California · NCT04907643

• Dual-target CAR-T therapy targeting mesothelin and CLDN18.2 for advanced pancreatic cancer

  This treatment will try sequential CAR‑T cell infusions that target mesothelin and CLDN18.2 in people with unresectable or metastatic pancreatic adenocarcinoma who have received prior systemic therapy.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07066995

• Early detection of pancreatic cancer using exosome-based biomarkers

  This study is testing a new way to find pancreatic cancer early by looking at tiny particles in the blood that carry specific markers.

  Recruiting at 11 sites City of Hope Medical Center · Phoenix, Arizona and 12 other locations · NCT06388967

• Investigating microRNA for diagnosing and treating pancreatic cancer

  This study is testing whether certain tiny molecules in the blood can help doctors diagnose pancreatic cancer earlier and see how well treatments are working for patients.

  Recruiting Nuvance Health · Norwalk, Connecticut · NCT04406831

• Treatment for metastatic cancer with BRCA or PALB2 mutations using chemotherapy and stem cells

  This study is testing a new treatment combining chemotherapy and stem cells for people with metastatic pancreatic or breast cancer who have BRCA or PALB2 mutations to see if it is safe and effective.

  Recruiting Phase 1 General Oncology, Inc. · Boston, Massachusetts and 1 other locations · NCT04150042

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.